Cholesterol in mild cognitive impairment and Alzheimer’s disease in a birth cohort over 14 years
- 536 Downloads
Animal epidemiological and clinical studies suggest that cholesterol is a risk factor for Alzheimer’s disease (AD). Nevertheless, the relation of cholesterol to mild cognitive impairment (MCI), influence of APOE genotype and its changes in lifespan is controversial. We investigated the potential impact of plasma total cholesterol (TC) on development of MCI and AD in the interdisciplinary longitudinal study on adult development and aging, a representative birth cohort (born 1930–1932), examined in 1993/1994 (VT1), 1997/1998 (VT2), and 2005/2007 (VT3). Of 500 participants at baseline, 381 survived and were examined at VT3. After exclusion of participants with lifetime prevalence of major psychiatric diseases or mild cognitive disorder due to a medical condition, 222 participants were included in the analysis. At VT3, 82 participants had MCI, 22 participants had AD, and 118 were in good health. Participants with MCI and AD at VT3 evidenced higher TC levels at VT1 than those who were healthy. Higher TC levels at baseline were associated with an increased risk for cognitive disorders at VT3 (highest vs. lowest quartile: OR 2.64, 95 % CI 1.12–6.23, p < 0.05). Over the 14 year follow-up, TC levels declined in those with MCI and AD, but remained stable in those who remained healthy. These findings were not modified by APOE genotype or use of cholesterol-lowering medications. Our findings demonstrate that higher TC levels are observed long before the clinical manifestation of MCI and AD in patients without psychiatric or somatic comorbidities and are independent of APOE genotype.
KeywordsAACD AD APOE Cholesterol ILSE MCI
The interdisciplinary longitudinal study on adult development and aging (ILSE) was supported by the “Research Program of the State of Baden-Württemberg” and the “Federal Ministry for Family, Senior Citizen, Women, and Youth, Germany.” P. Toro and J. Schröder received additional support by the “Marsilius Kolleg,” center of advanced studies, University of Heidelberg, Germany. This work was supported by the European Commission under the 7th Framework Programme of the European Union “Therapeutic and preventive impact of nutritional lipids on neuronal and cognitive performance in aging, Alzheimer’s disease and vascular dementia” coordinated by Prof Dr. Tobias Hartmann.
Conflict of interest
P. Toro, CH. Degen, D. Gustafson, M.Pierer, P. Schönknecht and J. Schröder declare no conflict of interest.
- 2.Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137(3):149–155PubMedCrossRefGoogle Scholar
- 11.Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, Frangione B, Ghiso J (2000) Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid beta peptides. Biochem J 348(Pt 2):359–365PubMedCentralPubMedCrossRefGoogle Scholar
- 16.Wittchen H, Zaudig M, Schramm E, Spengler P, Mombour W, Klug J, Horn R (1991) Strukturiertes klinisches Interview für DSM-III-R. Beltz-Test, GöttingenGoogle Scholar
- 18.McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34(7):939–944PubMedCrossRefGoogle Scholar
- 22.Oswald W, Fleischmann V (1991) Nürnberger Alters–Inventar. Universität Erlangen-Nürnberg, ErlangenGoogle Scholar
- 23.Sturm W, Willmes K, Horn W (1993) Leistungsprüfsystem für 50-90jährige. Hogrefe, GöttingenGoogle Scholar
- 24.Brickenkamp R (1978) Test d2: Aufmerksamkeits–Belastungs-test. Hofgrefe, GöttingenGoogle Scholar
- 25.Tewes W (1991) HAWIE-R: Hamburg–Wchsler–Intelligneztest für Erwachsene, revision. Huber, BernGoogle Scholar
- 27.Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62(10):1556–1560. doi: 10.1001/archneur.62.10.1556 PubMedCrossRefGoogle Scholar
- 32.Mielke M, Zandi P, Shao H, Waern M, Östling S, Guo X, Björkelund C, Lissner L, Skoog I, Gustafson D (2010) The 32 year relationship between cholesterol and dementia from mid- to late-life. Neurology 75(21):1888–1895Google Scholar
- 36.Hall K, Murrell J, Ogunniyi A, Deeg M, Baiyewu O, Gao S, Gureje O, Dickens J, Evans R, Smith-Gamble V, Unverzagt FW, Shen J, Hendrie H (2006) Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology 66(2):223–227. doi: 10.1212/01.wnl.0000194507.39504.17 PubMedCentralPubMedCrossRefGoogle Scholar
- 42.Beydoun MA, Beason-Held LL, Kitner-Triolo MH, Beydoun HA, Ferrucci L, Resnick SM, Zonderman AB (2011) Statins and serum cholesterol’s associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health 65(11):949–957. doi: 10.1136/jech.2009.100826 PubMedCentralPubMedCrossRefGoogle Scholar